Follow The Filings

Johnson & Johnson

New Brunswick, NJ 7 processed 13Fs on this site, 2025 Q3 to 2026 Q3

  • $762M
  • 15 holdings
  • 2026 Q3
  • −4.6% QoQ
  • Top 5 89.3%

Portfolio

2026 Q3, filed 10/26/2026, top 12 of 15 holdings

Top 5 89.3%, top 10 98.8%

  1. PTGX, Protagonist Therapeutics 45.3%
  2. NBTX, Nanobiotix 23.0%
  3. MGTX, Meiragtx 9.6%
  4. RAPP, Rapport Therapeutics 7.9%
  5. CTNM, Contineum Therapeutics 3.5%
  6. CBRS, Cerebras Systems 3.0%
  7. Xencor 2.4%
  8. Legend Biotech 2.1%
  9. FATE, Fate Therapeutics 1.1%
  10. CVRX 0.9%
  11. PRCT, Procept Biorobotics 0.9%
  12. NMRA, Neumora Therapeutics 0.1%
  13. Other 0.2%

AUM over time

2026 Q3 $762M −4.6% QoQ
2025 Q3: $504M 2025 Q3: $504M
Q3 2025
2025 Q4: $555M, +10.1% QoQ 2025 Q4: $555M, +10.1% QoQ
Q4
2026 Q1: $652M, +17.5% QoQ 2026 Q1: $652M, +17.5% QoQ
Q1 2026
2026 Q2: $799M, +22.5% QoQ 2026 Q2: $799M, +22.5% QoQ
Q2
2026 Q3: $762M, −4.6% QoQ 2026 Q3: $762M, −4.6% QoQ
Q3

Book

2025 Q3, filed 13 Nov, long equity only

Download CSV Download Excel
PTGX, Protagonist Therapeutics 32.30% Hold 2,449,183 $66.43 $163M
NBTX, Nanobiotix 21.09% Hold 5,623,816 $18.89 $106M
MGTX, MeiraGTx 10.85% Hold 6,641,064 $8.23 $55M
RAPP, Rapport Therapeutics 10.52% Hold 1,784,517 $29.70 $53M
CVRX 6.57% Hold 4,103,430 $8.07 $33M
Legend Biotech 5.27% Hold 814,586 $32.61 $27M
CTNM, Contineum Therapeutics 4.62% Hold 1,979,173 $11.75 $23M
PRCT, Procept BioRobotics 2.54% Hold 357,939 $35.69 $13M
Xencor 1.74% Hold 748,062 $11.73 $8.8M
ARWR, Arrowhead Pharmaceuticals 1.70% Hold 247,598 $34.49 $8.5M
FATE, Fate Therapeutics 0.85% Hold 3,379,064 $1.26 $4.3M
NMRA, Neumora Therapeutics 0.67% Hold 1,849,445 $1.82 $3.4M
Vor Biopharma 0.52% Hold 53,732 $48.72 $2.6M
Rallybio 0.36% Hold 3,636,363 $0.4990 $1.8M
LYEL, Lyell Immunopharma 0.13% Hold 41,165 $16.24 $669K
Nano-X Imaging 0.12% Hold 158,852 $3.70 $588K
LAB, Standard BioTools 0.08% Hold 311,967 $1.30 $406K
Adicet Bio 0.06% Hold 364,472 $0.8102 $295K
BiomX 0.01% Hold 96,866 $0.5250 $51K
Senseonics 0.00% Hold 54,621 $0.4358 $24K

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top.

Filings history

5 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q3 15 $762M −4.6% 13F-HR 10/26/2026 000090445426000541
2026 Q2 15 $799M +22.5% 13F-HR 8/6/2026 000090445426000435
2026 Q1 16 $652M +17.5% 13F-HR 5/13/2026 000090445426000280
2025 Q4 17 $555M — RESTATEMENT 3/18/2026 000090445426000192
2025 Q4 17 $555M +10.1% 13F-HR 2/13/2026 000090445426000111
2025 Q3 20 $504M — RESTATEMENT 3/18/2026 000090445426000190
2025 Q3 20 $504M — 13F-HR 11/13/2025 000090445425000587

About

Johnson & Johnson

7 processed 13Fs on this site, 2025 Q3 to 2026 Q3

SEC filing name
JOHNSON & JOHNSON
Location
New Brunswick, NJ
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf